(Sharecast News) - Swiss pharmaceutical giant Novartis raised its full-year guidance Tuesday after beating expectations in its first quarter.
The company attributed its performance to increased use of its psoriasis and arthritis drug Cosentyx.

Novartis said it now expected a high-single to low double-digit percentage growth in net sales for...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE